

Resource Summary Report

Generated by [ASWG](#) on Aug 3, 2026

Leica: STELLARIS 8 microscope

RRID:SCR_024664

Type: Tool

Proper Citation

Leica: STELLARIS 8 microscope (RRID:SCR_024664)

Resource Information

URL: <https://www.leica-microsystems.com/products/confocal-microscopes/p/stellaris-8/>

Proper Citation: Leica: STELLARIS 8 microscope (RRID:SCR_024664)

Description: STELLARIS 8 microscope with core system addition of spectrum WLL and specialized detector options of Power HyD family to expand range of confocal applications. Can be combined with all Leica Microsystems modalities, including FAsT Lifetime CONTRast (FALCON), Deep In Vivo Explorer (DIVE), STED, Digital Light Sheet (DLS) and CARS. STELLARIS 8 new features maximize the potential of these modalities.

Resource Type: instrument resource

Keywords: Microscope, Power HyD detectors, Leica Microsystems modalities,

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_024664.pdf

Resource Name: Leica: STELLARIS 8 microscope

Resource ID: SCR_024664

Alternate IDs: Model_Number_STELLARIS 8

Alternate URLs: <https://microscopy.anu.edu.au/files/Brochure-Leica-Stellaris.pdf>

Record Creation Time: 20231027T050251+0000

Record Last Update: 20260801T190819+0000

Ratings and Alerts

No rating or validation information has been found for Leica: STELLARIS 8 microscope.

No alerts have been found for Leica: STELLARIS 8 microscope.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Lasse Opsahl EL, et al. (2026) Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation. Cancer research, 86(1), 22.

Zhang T, et al. (2025) Tumour-associated macrophage infiltration differs in meningioma genotypes, and is important in tumour dynamics. Journal of experimental & clinical cancer research : CR, 44(1), 162.

Zhang K, et al. (2024) A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer. Cell chemical biology, 31(11), 1942.